December 14, 2021 10:32 AM EST

Novartis enlists Molecular Partners on radioligand therapy discovery; Galera blames CRO error for PhIII failure — claims success after all

Paul Schloesser

Associate Editor

Amber Tong

Senior Editor

A setback in Covid-19 didn’t stop Novartis from teaming up with Molecular Partners again. And this time, they will be looking for radiopharmaceuticals.

Having bet …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis enlists Molecular Partners on radioligand therapy discovery; Galera blames CRO error for PhIII failure — claims success after all

Paul Schloesser

Associate Editor

Amber Tong

Senior Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

No­var­tis en­lists Mol­e­c­u­lar Part­ners on ra­di­oli­gand ther­a­py dis­cov­ery; Galera blames CRO er­ror for PhI­II fail­ure — claims suc­cess af­ter all

Associate Editor

Senior Editor

Sign up to read this article for free.

Novartis enlists Molecular Partners on radioligand therapy discovery; Galera blames CRO error for PhIII failure — claims success after all